Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
4 {) U/ f0 _; I/ A7 C e
+ j, M* O. J) G3 h0 K, A5 V; e
/ v7 D, n' E, E$ {Sub-category:0 h% y6 n: W# ~6 Z7 \# B
Molecular Targets & I- }# S4 c" u6 L: k, a( P
$ m1 S1 d5 q; Z2 u
1 ~& q9 M1 X) ^Category:
: y# {1 i& A0 j& i- G% r& f; zTumor Biology
4 ^& R3 g/ W# h3 i4 \- @7 T3 m7 B* U, S: j7 y0 \
, {. Q3 e6 l% t. i# ~
Meeting:
, `/ @" r8 E/ N/ ]. o$ n2011 ASCO Annual Meeting
. K1 h( x" a d' Z" P8 Y
# `3 d& Q" e2 l) w3 f) K9 H* [; S7 n+ g2 {+ ]) z* d p
Session Type and Session Title:& R8 x+ u; R* g( G( n9 ~1 y
Poster Discussion Session, Tumor Biology
2 y, R f% |+ N* l7 g# z$ ^4 b# t$ E" W
# q. q. Z) D' Z; p9 Q, ]" _ lAbstract No:
; {4 {$ b/ n2 }/ ~10517 $ W6 n( _0 l* K ~; g0 U$ k
" g1 F" q; O: I8 n0 x9 H
: L$ f$ c3 N4 e) j SCitation:" H% f3 m* D& C7 \ D( X
J Clin Oncol 29: 2011 (suppl; abstr 10517)
" l6 s4 `$ {* q0 d/ t5 L" T
5 o% m* i; k/ m, n. E* l3 o7 T1 v% |
Author(s):
! ]3 S, Q7 U- B! ?, @. ~) D6 ]J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
9 D% j" C7 G9 u% p2 ?# t* F7 \7 Z) M) r9 \
. |1 W, l. t) |2 s+ q0 R9 T
, ^6 a8 M3 B# r! R( j4 L/ L( lAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
2 ~" u }; {, s$ }# B- v4 e6 N5 P; }
Abstract Disclosures: Q2 I9 S1 w; s, N
- c4 Q, U& j8 `2 W. \) g3 F" l
Abstract:
4 [9 ?; } O% b# C9 B
0 S; U" r$ r; `
- @6 a. q; z! M |Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.# W7 ]; j* r" X B
3 K# a9 X7 j$ O- S8 R
5 ^) t4 ]7 R/ H9 D1 n9 f# C |